1

2 Title: A first-in-human clinical study of an intranasal spray of a cocktail containing two

3 synergetic antibodies neutralizes Omicron BA.4/5

4 **Authors:**

- 5 Xinghai Zhang^{1†}, Feiyang Luo^{2,3†}, huajun Zhang^{1†}, Hangtian Guo^{4,7†}, Junhui Zhou^{1,5†}, Tingting
- 6 Li^{2,3†}, Shaohong Chen^{1,5†}, Shuyi Song^{2,3}, Meiying Shen⁶, Yan Wu¹, Yan Gao^{7,8}, Xiaojian Han^{2,3},
- 7 Yingming Wang^{2,3}, Chao Hu^{2,3}, Xiaodong Zhao⁹, Huilin Guo⁹, Dazhi Zhang⁹, Yuchi Lu⁷, Wei
- 8 Wang¹⁰, Kai Wang¹¹, Ni Tang¹¹, Tengchuan Jin¹², Menglu Ding¹³, Shuhui Luo¹³, Cuicui Lin¹³,
- 9 Tingting Lu¹³, Bingxia Lu¹³, Yang Tian¹³, Chengyong Yang¹³, Guofeng Cheng¹³*, Haitao
- 10 Yang^{7,8}*, Aishun Jin^{2,3}*, Xiaoyun Ji^{4,10,14}*, Rui Gong¹*, Sandra Chiu¹²*, Ailong Huang¹¹*

11 Affiliations:

¹CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center

13 for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430071, China

- ¹⁴ ²Department of Immunology, College of Basic Medicine, Chongqing Medical University,
- 15 Chongqing 400010, China.

¹⁶ ³Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology,

- 17 Chongqing Medical University, Chongqing 400010, China.
- ⁴The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Institute
- 19 of Viruses and Infectious Diseases, Chemistry and Biomedicine Innovation Center (ChemBIC),
- 20 Institute of Artificial Intelligence Biomedicine, Nanjing University, Nanjing 210023, China.
- ⁵University of Chinese Academy of Sciences, Beijing 100049, China

- ⁶Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical
- 23 University, Chongqing 400010, China.
- ²⁴ ⁷Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and
- 25 Technology, Shanghai Tech University, Shanghai 201210, China.
- ²⁶ ⁸Shanghai Clinical Research and Trial Center, Shanghai 201210, China
- ²⁷ ⁹The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
- ²⁸ ¹⁰Institute of Life Sciences, Chongqing Medical University, Chongqing 400010, China.
- ²⁹ ¹¹Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute
- 30 for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital,
- 31 Chongqing Medical University, Chongqing, 400010 China.
- ³² ¹²Division of Life Sciences and Medicine, University of Science and Technology of China,
- 33 Hefei, Anhui 230026, China
- ¹³Mindao Haoyue Co., Ltd., SQ0042 Lanyuan Hall, No.61 Daxuecheng Middle Road,
- 35 Chongqing, 400042 China
- ¹⁴Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing
 210023, China.
- ³⁸ †These authors contributed equally to this work.
- 39 *Corresponding authors: Haitao Yang (yanght@shanghaitech.edu.cn), Aishun Jin
- 40 (aishunjin@cqmu.edu.cn), Xiaoyun Ji (xiaoyun.ji@nju.edu.cn), Rui Gong (gongr@wh.iov.cn),
- 41 Sandra Chiu (qiux@ustc.edu.cn), Ailong Huang (ahuang@cqmu.edu.cn)
- 42

43 **One Sentence Summary:**

- 44 An intranasal spray of two synergetic antibodies cocktail neutralizing Omicron BA.4/5 and an
- 45 initial clinical evaluation in healthy volunteers.

46

47 Abstract:

Neutralizing monoclonal antibodies (NAbs) with prophylactic and therapeutic efficacy have 48 demonstrated fundamental importance in the control of SARS-CoV-2 transmission. However, 49 their wide application has been largely limited by high cost and inconvenience in administration. 50 Here, we developed an intranasal spray containing two synergetic human NAbs that could 51 broadly neutralize the emerging Omicron variants in vitro. A unique synergetic neutralizing 52 mechanism was identified that the two NAbs bound to exclusive epitopes on the RBD and 53 structurally compensate each other in blocking the Spike-ACE2 interaction. Importantly, when 54 given at low dosages for three consecutive days through the intranasal mucosal route, this 55 56 cocktail showed significant improvement in the emergency preventive and therapeutic effects in hamsters challenged with authentic Omicron BA.1. Further, we performed an investigator-57 initiated trail in healthy volunteers (ChiCTR2200066525) to study the safety and 58 59 pharmacokinetics of the antibody cocktail administrated as nasal spray. The nasal spray is generally safe and well tolerated without treatment related severe abnormal effects. The antibody 60 cocktail nasal spray demonstrated nasal concentrations higher than the IC₉₀ of neutralization 61 activity against Omicron BA.4/5 even at 24 hours post dosing. Furthermore, nasal samples from 62 the study subjects demonstrated potent neutralization activity against Omicron BA.4/5 in an ex 63 vivo pseudovirus neutralization assay. Together, we provide a novel approach for NAb regimens, 64 a potentially highly effective product with broad applicable perspective in depressing the 65 infection risk of new epidemic variant and ameliorating the heavy medical burden of hospital. 66

67

68 Main Text:

69 **INTRODUCTION**

70 Since the outburst of COVID-19 in December 2019, SARS-CoV-2 continues to evolve substantially, acquiring sets of mutations that enhance its transmissibility, infectivity and the 71 ability to escape natural and acquired immunity (1-3). Contrast to other variants that 72 preferentially engage in the lungs, Omicron alters the route of viral entry into host cells and is 73 74 prompted to replicate in the upper airway (4-6). This causes more asymptomatic infections contributing to silent spread of the virus and poses substantial difficulties for effective prevention 75 for the spread of infection (7-9). Omicron and its sub variants exhibit dramatic antigen shift, 76 which have been shown to render the booster vaccination or recovery sera ineffective and cause 77 78 breakthrough infections (10-13). Recent studies further hampered the active immune protection with evidences of inadequate protection against Omicron sublineages from vaccinated boosters 79 based on Omicron BA.1 (14-16). Moreover, Paxlovid, a combination of two small molecule 80 81 inhibitors recently received emergency authorization for patients at higher risk of critical illness, 82 failed to prevent close contact infection in family members living with patients (17-19). Thus, 83 alternative and supplemental prophylactic drugs are now urgently needed to prevent Omicron 84 infection and subsequently block its transmission in the community (20-22). 85 Passive antibody administration based on neutralizing antibodies (NAbs) have

demonstrated protective efficacy in susceptible individuals with moderated-to-severe immune compromise or vaccination contraindication, with promising potential in breaking the transmission chain (23-25). However, the high cost and the inconvenient intramuscular or intravenous way of administrations have drastically limited its application in broad population (20, 26, 27). To overcome these practical drawbacks, passive transfer inhibitors through the

91	intranasal mucosal route may be promising approach to prevent the spread of Omicron (28-31).
92	Antibodies delivery through an inhalant has been shown to facilitate early-stage contact with the
93	pathogen in the respiratory tract (32-34). This may serve as an applicable platform enabling
94	NAbs enrichment in the route of viral entry (e.g. nasal cavity and the upper airway), and
95	overcoming the low and unsatisfying distribution of NAbs at the site of infection when
96	administered routinely through a systemic route (35-37).
97	Here, we identified an intranasal applicable cocktail with broad neutralizing capability
98	against Omicron and its sublineages, and determined its synergetic mechanism. We further
99	investigated the prophylactic and treatment efficacy of this cocktail against Omicron BA.1 in a
100	hamster model and evaluated its potential capability of the nasal spray convenient for self-
101	administration to block the infection of BA.4/5 in a first-in-human trial.
102	KESULIS
102 103	Broad neutralizing ability of the cocktail containing 58G6 and 55A8
102 103 104	Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early
102 103 104 105	RESULTS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its
102 103 104 105 106	RESULTSBroad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and itsmutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked
 102 103 104 105 106 107 	RESULTS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed
102 103 104 105 106 107 108	 RESOLIS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and
 102 103 104 105 106 107 108 109 	RESOLIS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level (<10 ⁻¹² M)
102 103 104 105 106 107 108 109 110	RESULTS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level (<10 ⁻¹² M) (fig. S1C). Further, we confirmed that cocktail of 55A8 and 58G6 could neutralize the
 102 103 104 105 106 107 108 109 110 111 	RESOLTS Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level (<10 ⁻¹² M) (fig. S1C). Further, we confirmed that cocktail of 55A8 and 58G6 could neutralize the pseudoviruses of SARS-CoV-2 variant strains (Fig. 1A, and fig. S2A and B). Interesting, the
 102 103 104 105 106 107 108 109 110 111 112 	Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level (<10 ⁻¹² M) (fig. S1C). Further, we confirmed that cocktail of 55A8 and 58G6 could neutralize the pseudoviruses of SARS-CoV-2 variant strains (Fig. 1A, and fig. S2A and B). Interesting, the cocktail of 58G6 and 55A8 demonstrated obviously synergetic effects against pseudotyped
 102 103 104 105 106 107 108 109 110 111 112 113 	Broad neutralizing ability of the cocktail containing 58G6 and 55A8 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early 2019 (<i>31, 38-40</i>). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level (<10 ⁻¹² M) (fig. S1C). Further, we confirmed that cocktail of 55A8 and 58G6 could neutralize the pseudoviruses of SARS-CoV-2 variant strains (Fig. 1A, and fig. S2A and B). Interesting, the cocktail of 58G6 and 55A8 demonstrated obviously synergetic effects against pseudotyped SARS-CoV-2 variants as well as the authentic Omicron BA.1, with the half inhibition

- 114 concentration exponentially lower than the currently approved NAbs for the emergence
- treatment of COVID-19 (Fig. 1A and B). Therefore, this cocktail consisted of potent neutralizers
- 116 58G6 and 55A8 with synergetic potency and breadth against the Omicron variants.
- 117 Synergetic neutralizing mechanism of this cocktail
- 118 To investigate the neutralizing mechanism of the 55A8, we first studied the single-
- 119 particle cryo-electron microscopy (cryo-EM) structures of the antigen-binding fragments (Fabs)
- 120 of 55A8 in complex with the prefusion Omicron BA.1 S trimer (fig. S3A). In all observed 55A8
- 121 Fabs-S complexes, the S trimer adopted a "1-up/2-down" or a "2-up/1-down" conformation (fig.
- 122 S3A and B). Superimposition of the down RBD in the structures of the 55A8 Fab-S and ACE2-S
- 123 complexes revealed that a 55A8 Fab binding with a down RBD could create a steric clash
- between ACE2 and the adjacent up RBDs, while no overlap between the 55A8 Fab and ACE2 on
- 125 the same up RBD were observed (Fig. 2A).

126 Next, the cryo-EM structures of the Omicron BA.1 S trimer in complex with the 55A8 127 and 58G6 Fabs were determined and similar conformation of the BA.1 S trimer were observed 128 when treated with the NAb-cocktail (fig. S3C). A refinement to an overall resolution of 3.3 Å showed that the majority of the selected particle images represented a 4-Fab-per-trimer complex, 129 containing three 55A8 Fabs and one 58G6 (fig. S3D). Specifically, we found that 55A8 and 130 131 58G6 Fab simultaneously bound to a single up RBD, which exhibited no conformational changes comparing with the BA.1 S-55A8 Fab complex (Fig. 2B). The addition of 58G6 occupied the 132 ACE2 binding site on the 55A8-bound RBD and further occluded the accessibility of the 133 134 Omicron BA.1 S protein to ACE2 (Fig. 2C and D). This was further evidenced by the ACE2 competition assay, in which 55A8 showed no competition with ACE2 for binding to the 135 Omicron BA.1 RBD, but partially competed with ACE2 for binding to the Omicron BA.1 S 136

137	protein (fig. S4A). Also, we confirmed that 58G6 and 55A8 could simultaneously bind to the S
138	proteins of SARS-CoV-2 Omicron BA 1 and Omicron BA 2 in a noncompetitive manner (fig
150	proteins of 574x5 CoV 2, Onneron D7x1 and Onneron D7x2 in a noncompetitive manner (fig.
139	S4B). These findings suggested that the synergetic neutralization might be achieved through
140	complementary steric occlusion of ACE2 by the pair of 55A8 and 58G6.
141	To determine the binding epitopes of these NAbs on Omicron BA.1 S proteins, we
142	assessed the potential hydrogen bonds of 55A8 and 58G6 complementarity determining regions
143	(CDRs) (fig. S5A to D). Specifically, half of the six (CDRs; CDRH3, CDRL1 and CDRL3) of
144	the 55A8 Fab were found to directly participate in the interactions with the $S^{345-352}$ and $S^{440-450}$
145	regions (fig. S6A and B). Several potential hydrogen bonds, including R346, Y351, K440, S443,
146	K444, V445 and N450, were identified at the interface of the 55A8 Fab and Omicron RBD (fig.
147	S6C). The CDRs of 58G6 were shown to form unique interactions with the mutated amino acids
148	N477, K478 and R493 within Omicron BA.1 RBM, explaining the sustained neutralizing
149	capability of this RBM-targeted NAb against the Omicron BA.1 variants (fig. S6D).
150	Intranasal delivery of this cocktail protect hamster from Omicron challenge
151	The protective efficacy of the cocktail of 55A8 and 58G6 against Omicron BA.1
152	infection were verified in a hamster model. On Day 0, hamsters received a single intranasal
153	administration of 1500 μg 58G6, 500 μg 55A8 or combination of 300 μg 55A8 with 1000 μg
154	58G6 one hour prior to a challenge with 10^4 plaque forming unit (PFU) of Omicron BA.1
155	through nasal drips (Fig. 3A). Post-infection, two additional NAb(s) treatments were given at day
156	1 and 2, and the animals were sacrificed one day later (Fig. 3A). RT-qPCR and plaque assays
157	with harvested trachea and lungs tissues showed that viral RNA copies and infectious virus loads
158	were significantly reduced (Fig. 3B and C). Importantly, the cocktail treatment resulted in robust

viral clearance both in the upper respiratory tract (turbinate and trachea) and lower respiratorytract (lungs).

Further, we investigated the protective efficacy of this cocktail with lower dosages and a 161 prolonged pretreatment time (Fig. 3D). Significant decrease in the viral RNA copies were found 162 in the trachea and lung tissues, and the infectious viral load was reduced substantially even with 163 remarkably low dose of the cocktail treatment ($25 \ \mu g \ 55A8 + 25 \ \mu g \ 58G6$) (Fig. 3E and F). 164 Encouraged by the observed protective effects associated with the cocktail spray, we analyzed 165 the emergency treatment potential of 55A8 alone and the cocktail at 3 h post-infection (Fig. 3G). 166 Expectedly, post-infection administration of 55A8 or the cocktail did not affect viral copies 167 168 detected in the airway tissues (Fig. 3H). However, 55A8 profoundly impacted successful viral assembly, indicated by the significant reduction of virus load in both lungs (Fig. 3I). These data 169 showed that the cocktail of 55A8 and 58G6 could confer protection even at markedly low doses 170 171 and displayed a potential applicable value in the emergency treatment through the convenient administration with intranasal delivery. 172

173 First-in-human trial of 55A8 and 58G6 antibody cocktail in healthy volunteers

174 A cocktail of 55A8 and 58G6 at 4:1 mass ratio was selected based on neutralization activity against Omicron BA.4/5 pseudovirus (Table S1). A formulation of 5 mg/mL total 175 176 antibody concentration for the cocktail filled in a nasal spray device for self-administration was produced under Good Manufacturing Practice (GMP). This 4:1 combination of 55A8 and 58G6 177 at 5 mg/mL is called "A8G6" antibody cocktail. A8G6 cocktail had studied for preclinical 178 179 toxicity in Rhesus monkeys under Good Laboratory Practice (GLP) and no safety concern was observed. A first-in-human randomized and placebo-controlled trial on the intranasal delivery of 180 181 the antibody cocktail was conducted in 108 healthy volunteers (Fig. 4) to assess the

182 safety/tolerability (primary objective) and pharmacokinetics (nasal and serum concentration over 183 time, secondary objective) of A8G6 nasal spray. The baseline demographic information of the 184 study subjects is listed in Table S2 and A8G6 versus placebo is 5 to 1 in all cohorts. The trial 185 started with cohort 1, in which different doses (ranging from one dose to four doses per day) 186 were given within one day (Fig. 4). In cohort 2, 3 and 4, four doses per day were given for 3, 7 187 and 14 consecutive days. Overall, A8G6 nasal spray is well tolerated with minimum treatment

related adverse effects (Table S3 and S4) and the primary objective was met.

In second objective of the trial, the pharmacokinetics of A8G6 nasal spray was studied to 189 optimize the dosing regimen. The target concentration is defined as nasal concentration above 190 191 BA.4/5 pseudovirus neutralization IC_{90} , which is about 5000 ng/mL. The results showed that after a single dose nasal administration, nasal concentration of A8G6 can maintain above BA.4/5 192 neutralization IC₉₀ for 8 hours in > 90% subjects and dropped to below BA.5 IC₉₀ at 24 hours 193 194 post single dose for >50% of subjects (Fig. 5A). This suggests that multiple doses are required to maintain nasal concentration above BA.4/5 IC₉₀ throughout the entire day. Similarly, two doses 195 of nasal spray separated by 4 hours can maintain nasal concentration above IC₉₀ 8 hours post 2nd 196 dose but cannot provide 24 hours coverage (Fig. 5B). When dosed at 2*0.7 mg per dose, nasal 197 concentration of A8G6 was similar to 0.7 mg per dose (Fig. 5A and C). Four doses of A8G6 at 4 198 hours per dose, however, can achieve nasal concentration above BA.4/5 IC₉₀ at 24 hours post 1st 199 dose or until the 1st dose of next day (Fig. 5D). Collectively, cohort 1 data suggest that higher 200 201 dose than 0.7 mg per dose does not result in higher nasal A8G6 concentration; repeat dosing 202 during the day is required to maintain nasal concentration above the target concentration of BA.4/5 IC₉₀. 203

Since each dose of 0.7 mg can maintain 8 hours coverage above BA.4/5 IC₉₀, the dosing 204 frequency could be changed to 3 doses per day at 8 hours per dose. When dosing for multiple 205 consecutive days (3, 7 and 14 days), the nasal concentration at the end of the dosing was similar 206 to day 1, suggesting minimum accumulation of A8G6 in nasal cavity over multiple days of 207 dosing (Fig. 6A to C). To study the amount of A8G6 cocktail entering systemic blood 208 209 circulation, we developed an ELISA assay that can specifically detect 58G6 in human serum using anti-58G6 specific antibodies. The results showed that for trail subjects in repeat dosing 210 cohort 3 and 4, the serum 58G6 concentrations are below the detection limit (0.5 ng/mL) at the 211 212 beginning and at the end of dosing period. This suggested that A8G6 has minimum penetration in the systemic blood circulation, which is consistent with the fact that antibody is a large 213 molecule that has limited permeability through the nasal mucosa. Further, we studied the 214 pharmacodynamics of A8G6 cocktail nasal spray by testing the nasal samples from the study 215 subjects for ex vivo neutralization activity against Omicron BA.4/5 (Fig. 7). The results 216 confirmed more than 90% BA.4/5 neutralization activity in all the samples. This human nasal 217 pharmacokinetics/pharmacodynamics (PK/PD) data provided a good basis for potential clinical 218 efficacy of this nasal spray for preventing Omicron BA.5 infections. 219

220 **DISCUSSION**

Given the identified rapid loss of protection by vaccination against SARS-CoV-2, the ontime NAb injection has been shown with timely prophylactic efficacy but has limited range of application, due to the high cost and inconvenience in administration (20-22). In this study, we identified two synergetic NAbs that could broadly neutralize the emerging Omicron variants. Synergetic neutralizing mechanism was found to largely rely on a unique complimentary addition of an RBM-targeted NAb (58G6) to a non-RBM NAb 55A8 to completely occlude

227	ACE2 accessibility, with potential mutual inhibitions for the occurrence of escape mutations
228	often seen with long-term application (41-43). This might greatly support the current lack of
229	single NAb in face of Omicron and its sub variants that dramatically escape the majority of
230	existing SARS-CoV-2 NAbs, and put the cocktail at the center stage for the development of
231	clinically effective prophylactic regiments against the Omicron pandemic (44).

Together with the global attempt to provide affordable and accessible prophylactic drugs, 232 we have advanced 55A8/58G6 (A8G6) cocktail into animal and human studies and presented the 233 initial investigation by nasal spraying the NAb cocktail for the possibility of interrupting 234 Omicron transmission in community (20). As the upper air tract has been shown to be favored by 235 236 Omicron, several studies have proved evidences that intranasal pretreatment with small molecule inhibitor, anti-sense oligonucleotide (ASO) targeting SARS-CoV-2 RNA genome, anti-ACE2 237 mAb or mini-proteins mimicking hACE2 could effectively reduce respiratory virus replication 238 239 and prevent SARS-CoV-2 infection (28, 30, 32, 33, 45, 46). It is evident that our A8G6 nasal spray antibody works uniquely differently from those nasal delivery molecules, by well-240 characterized mechanism of action and specificity, favorable NAb drug properties, or low safety 241 risk with its local exposure. We further proved that the cocktail we identified could confer 242 protective efficacy even at a markedly low dose of 50 µg against authentic Omicron BA.1 243 challenge in the hamster model, suggesting an economic outlook for the medical cost with its 244 potential wide range applications. Together, all these features of A8G6 nasal spray provide 245 strong foundation for fast development into clinical studies in human, while to the best of our 246 247 knowledge, those other intranasal delivery molecules have not yet advanced into human studies or the clinical data have yet ready to be disclosed. This will make our study the first published 248 249 detailed PK/PD data on a nasal spray of neutralizing antibodies for the potential prevention of

Omicron, and the product based on this cocktail are currently undergone further clinical development to test for its applicable value in the prevention and emergency treatment against the Omicron pandemic (*44*).

The major challenge that arises with mucosal drug delivery comes from the rapid 253 physical clearance by the mucociliary system (47). In response, repeated administrations of our 254 NAbs and cocktail have shown with effective long-term protection, which may further reduce the 255 potential risk of entrapping the virus in the mucosa by virus-antibody complexes. This calls for 256 excellent biocompatibility with mAb products subjected for repetitive treatment. Hence, we 257 chose patient-derived NAbs with low immunogenicity over other designed proteins or NAbs 258 259 from other species, In addition, we utilized the IgG subtype of NAb to best restrict potential undesired immune responses. Although dimerized IgA are released into the upper airways and 260 may represent elevated protective capacity and optimal on-site pharmacodynamics, IgG exhibit 261 operational maturation in large-scale preparation with stable quality control between batches and 262 are better choice for the potential wide range application of the NAb-based nasal spray in 263 purpose of actual clinical use (32). Also, the fact that IgG is released to the lower lung through 264 passive transudation may better facilitate the emergency treatment effect of our cocktail. Finally, 265 the absence of immune response in the first-in-human trial of the cocktail NAb is encouraging 266 267 for the concept of using repetitive intranasal protective measurements in the long combat with continuous emerging SARS-CoV-2 mutational variants. 268

There are a few limitations with our study. First, due to the lag in the availability of authentic Omicron sublineages variants, in vitro neutralization experiments were performed against wild-type SARS-CoV-2 and only two mutants, Delta and Omicron BA.1. Future experiments with updated Omicron sublineages are needed to determine the antiviral activity of our cocktail against the full landscape of the Omicron clade. Second, the physiological
disparities of respiratory systems between human and rodent models raise questions for the
observed preventative effects. Excitingly, as projected based on the faster respiration rate of
rodents, cocktail 55A8/58G6 exhibited more persistent PK in human nasal cavity (Fig. 5A to D)
than in rodents. Certainly, thorough efficacy study in human trials is warranted to validate the
clinical efficacy of this cocktail.

In conclusion, we present a potent NAb cocktail against Omicron variants with high prophylactic efficacy at low dosage, which can be dosed in the self-administrable nasal spray format. The associated low cost and the needle-free convenience make it acceptable for potential large-scale application in general population. Our product represents promising passive NAbs interventions that may effectively aid the current prophylactic vaccines to mitigate the current SARS-CoV-2 transmission and its probable resurgence.

285 MATERIALS AND METHODS

286 Study design

The ultimate objective of this study was to collect the PK/PD information of an intranasal 287 spray of a human antibody cocktail A8G6 data in a first-in-human trail. At the outset, human IgG 288 antibodies with low immunogenicity were applied by means of intranasal spray and tested for the 289 efficiency of blocking SARS-CoV-2 infection. Specifically, two nAbs (55A8 and 58G6) were 290 selected from our screening library established before the dominance of Omicron BA.5, with 291 outstanding neutralizing potency and broad neutralizing ability characterized by BLI affinity 292 experiments and a standard pseudovirus and authentic virus neutralization assays. The specific 293 neutralizing mechanism of 55A8 were further assessed by cryoEM. The observed synergetic 294 295 neutralizing mechanism of 55A8 and 58G6 was addressed by structure analysis and confirmed by BLI competition assays of inhibiting RBD-ACE2 and Spike-ACE2 binding. 296

Next, we performed animal studies to determine whether low concentration of intranasal 297 298 delivered 55A8 and 58G6 could provide protective efficacy pre- and post-exposure of Omicron 299 BA.1 infection. Female hamsters (age of five to six weeks) were randomly assigned to groups. Animal researchers were not blinded to the study groups or during the assessment of the 300 outcomes. No data points were omitted for the analysis. Sample sizes were determined based on 301 302 previous experience. All the animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of the Institute of Wuhan Institute of Virology, Chinese 303 Academy of Sciences, and performed in an ABSL-3 facility (WIVA45202104). 304

This first-in-human trial was a randomized, double-blind, placebo-controlled study. A total of 108 healthy volunteers were enrolled into the study, each provided written informed consent in according with institutional guidelines. The trial is registered at Chinese Clinical Trial

Registry with registration # ChiCTR2200066525. The trial was conducted in accordance with the 308 Second Affiliated Hospital of Chongqing Medical University (Chongqing, China) Institutional 309 Ethics Review Board (Study # AY-62-8001). The ethical approval of this trial complies with the 310 requirements of the Good Clinical Practice, the Declaration of Helsinki of the World Medical 311 Association, International Ethical Guidelines on Biomedical Research Involving Human Subjects 312 of the Council for International Organizations of Medical Sciences, and relevant domestic laws 313 and regulations. The sample size was determined based on precise assess both the primary and 314 secondary objectives. The primary objective of this clinical study was to evaluate the safety and 315 tolerance of A8G6 nasal spray under continuous repetitive use. To this end, we recorded the 316 number of adverse events. The second objective was to evaluate the PK of A8G6 nasal spray to 317 optimize the dosing regimen. 318

For PK analysis, we collected the blood samples at 1 and 3 days after final dose in cohort 1-3, 319 and 3 and 7 days after final dose in cohort 4. Nasal swab was collected (\Box) at 0.25 and 4 hours 320 after the final dose from left nostril, 4 and 8 hours from right nostril, and day 2 and day 4 from 321 both nostrils in cohort 1a and 1c (Fig. 5A and 5C); (\Box) at 0.25 hours before and 4 hours after the 322 final dose from left nostril, 4 and 8 hours after the final dose from right nostril, and day 2 and 323 day 4 from both nostrils in cohort 1b and 1d (Fig. 5B and 5D); (\Box) at 0.5 hours before 2nd dose 324 on day 1 and 12 hours after last dose from left nostril, 0.5 hours before and 24 hours after last 325 dose from right nostril, and day 6 from both nostrils in cohort 2 (Fig. 6A); (\Box) at 0.5 hours 326 before 2nd dose on day 1 and 12 hours after last dose from left nostril, 0.5 hours before and 24 327 hours after last dose from right nostril, and day 10 from both nostrils in cohort 3 (Fig. 6B); (\Box) at 328 0.5 hours before 2nd dose on day 1, 15 mins before and 1 hours after last dose, and day 16 from 329 left nostril, 0.5 hours before 2nd dose on day 8, 4 and 12 hours after last dose from right nostril, 330

331	and day 17 and 21 from both nostrils in cohort 4 (Fig. 6C). The concentrations of A8G6 from
332	these samples were predicted by an ELISA assay containing a pair of specific anti-58G6
333	antibodies, and the corresponding neutralization activities of collected samples were measured
334	using an Omicron BA.5 pseudovirus neutralization assay. An independent data safety monitoring
335	committee performed trial oversight and made recommendations after review of safety
336	reports between cohorts. Full details of the trial design, conduct, oversight and sample analysis
337	and statistical analysis were provided in the protocol, which is available in the supplemental
338	data.Statistical methods
339	Statistical analyses of the animal studies were performed using GraphPad Prism software
340	v.9.2.0. Comparisons between two groups were performed using unpaired Student's t tests.
341	Comparisons among multiple groups were performed using one-way ANOVA followed by
342	Tukey's multiple comparison post hoc test. P \square < \square 0.05 was considered significant (significance
343	is denoted as follows: $P = < 0.05$, $P = < 0.01$, $P = < 0.001$, and $P = < 0.001$, and $P = < 0.0001$).
344	List of Supplementary Materials
345	Materials and Methods
346	Figs. S1 to S6
347	Tables S1 to S5
348	A8G6 IIT Protocol
349	References (48–60)
350	References and Notes

- 1. P. Mlcochova, S. A. Kemp, M. S. Dhar, G. Papa, B. Meng, I. Ferreira, R. Datir, D. A. Collier, A. Albecka,
- 352 S. Singh, R. Pandey, J. Brown, J. Zhou, N. Goonawardane, S. Mishra, C. Whittaker, T. Mellan, R. Marwal,

353		M. Datta, S. Sengupta, K. Ponnusamy, V. S. Radhakrishnan, A. Abdullahi, O. Charles, P. Chattopadhyay,
354		P. Devi, D. Caputo, T. Peacock, C. Wattal, N. Goel, A. Satwik, R. Vaishya, M. Agarwal, A. Mavousian, J.
355		H. Lee, J. Bassi, C. Silacci-Fegni, C. Saliba, D. Pinto, T. Irie, I. Yoshida, W. L. Hamilton, K. Sato, S.
356		Bhatt, S. Flaxman, L. C. James, D. Corti, L. Piccoli, W. S. Barclay, P. Rakshit, A. Agrawal, R. K. Gupta,
357		SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114-119 (2021).
358	2.	P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S.
359		Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y.
360		Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130-135
361		(2021).
362	3.	P. Wang, R. G. Casner, M. S. Nair, M. Wang, J. Yu, G. Cerutti, L. Liu, P. D. Kwong, Y. Huang, L.
363		Shapiro, D. D. Ho, Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell host &
364		<i>microbe</i> 29 , 747-751.e744 (2021).
365	4.	B. Meng, A. Abdullahi, I. Ferreira, N. Goonawardane, A. Saito, I. Kimura, D. Yamasoba, P. P. Gerber, S.
366		Fatihi, S. Rathore, S. K. Zepeda, G. Papa, S. A. Kemp, T. Ikeda, M. Toyoda, T. S. Tan, J. Kuramochi, S.
367		Mitsunaga, T. Ueno, K. Shirakawa, A. Takaori-Kondo, T. Brevini, D. L. Mallery, O. J. Charles, J. E.
368		Bowen, A. Joshi, A. C. Walls, L. Jackson, D. Martin, K. G. C. Smith, J. Bradley, J. A. G. Briggs, J. Choi,
369		E. Madissoon, K. B. Meyer, P. Mlcochova, L. Ceron-Gutierrez, R. Doffinger, S. A. Teichmann, A. J.
370		Fisher, M. S. Pizzuto, A. de Marco, D. Corti, M. Hosmillo, J. H. Lee, L. C. James, L. Thukral, D. Veesler,
371		A. Sigal, F. Sampaziotis, I. G. Goodfellow, N. J. Matheson, K. Sato, R. K. Gupta, Altered TMPRSS2 usage
372		by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706-714 (2022).
373	5.	H. Zhao, L. Lu, Z. Peng, L. L. Chen, X. Meng, C. Zhang, J. D. Ip, W. M. Chan, A. W. Chu, K. H. Chan, D.
374		Y. Jin, H. Chen, K. Y. Yuen, K. K. To, SARS-CoV-2 Omicron variant shows less efficient replication and
375		fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerging microbes &
376		infections 11, 277-283 (2022).
377	6.	K. P. Y. Hui, J. C. W. Ho, M. C. Cheung, K. C. Ng, R. H. H. Ching, K. L. Lai, T. T. Kam, H. Gu, K. Y. Sit,
378		M. K. Y. Hsin, T. W. K. Au, L. L. M. Poon, M. Peiris, J. M. Nicholls, M. C. W. Chan, SARS-CoV-2
379		Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715-720 (2022).
380	7.	T. Carvalho, Silent spread. Nature medicine 26, 1807 (2020).

381	8.	N. Garrett, A. Tapley, J. Andriesen, I. Seocharan, L. H. Fisher, L. Bunts, N. Espy, C. L. Wallis, A. K.
382		Randhawa, N. Ketter, M. Yacovone, A. Goga, L. G. Bekker, G. E. Gray, L. Corey, High Rate of
383		Asymptomatic Carriage Associated with Variant Strain Omicron. medRxiv : the preprint server for health
384		sciences, (2022).
385	9.	N. Garrett, A. Tapley, J. Andriesen, I. Seocharan, L. H. Fisher, L. Bunts, N. Espy, C. L. Wallis, A. K.
386		Randhawa, M. D. Miner, N. Ketter, M. Yacovone, A. Goga, Y. Huang, J. Hural, P. Kotze, L. G. Bekker, G.
387		E. Gray, L. Corey, High Asymptomatic Carriage with the Omicron Variant in South Africa. Clinical
388		infectious diseases : an official publication of the Infectious Diseases Society of America, (2022).
389	10.	N. Andrews, E. Tessier, J. Stowe, C. Gower, F. Kirsebom, R. Simmons, E. Gallagher, S. Thelwall, N.
390		Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, K. Brown,
391		S. Hopkins, M. Chand, S. N. Ladhani, M. Ramsay, J. Lopez Bernal, Duration of Protection against Mild
392		and Severe Disease by Covid-19 Vaccines. The New England journal of medicine 386, 340-350 (2022).
393	11.	N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, R. Sachdeva, C. Gower, M. Ramsay, J. Lopez Bernal,
394		Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and
395		death in England. Nature medicine 28, 831-837 (2022).
396	12.	T. K. Burki, Omicron variant and booster COVID-19 vaccines. The Lancet. Respiratory medicine 10, e17
397		(2022).
398	13.	C. Kuhlmann, C. K. Mayer, M. Claassen, T. Maponga, W. A. Burgers, R. Keeton, C. Riou, A. D.
399		Sutherland, T. Suliman, M. L. Shaw, W. Preiser, Breakthrough infections with SARS-CoV-2 omicron
400		despite mRNA vaccine booster dose. Lancet (London, England) 399, 625-626 (2022).
401	14.	S. A. Costa Clemens, L. Weckx, R. Clemens, A. V. Almeida Mendes, A. Ramos Souza, M. B. V. Silveira,
402		S. N. F. da Guarda, M. M. de Nobrega, M. I. de Moraes Pinto, I. G. S. Gonzalez, N. Salvador, M. M.
403		Franco, R. N. de Avila Mendonça, I. S. Queiroz Oliveira, B. S. de Freitas Souza, M. Fraga, P. Aley, S.
404		Bibi, L. Cantrell, W. Dejnirattisai, X. Liu, J. Mongkolsapaya, P. Supasa, G. R. Screaton, T. Lambe, M.
405		Voysey, A. J. Pollard, Heterologous versus homologous COVID-19 booster vaccination in previous
406		recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority,
407		single blind, randomised study. Lancet (London, England) 399, 521-529 (2022).

408	15.	C. J. Reynolds, C. Pade, J. M. Gibbons, A. D. Otter, K. M. Lin, D. Muñoz Sandoval, F. P. Pieper, D. K.
409		Butler, S. Liu, G. Joy, N. Forooghi, T. A. Treibel, C. Manisty, J. C. Moon, A. Semper, T. Brooks, Á.
410		McKnight, D. M. Altmann, R. J. Boyton, H. Abbass, A. Abiodun, M. Alfarih, Z. Alldis, D. M. Altmann, O.
411		E. Amin, M. Andiapen, J. Artico, J. B. Augusto, G. L. Baca, S. N. L. Bailey, A. N. Bhuva, A. Boulter, R.
412		Bowles, R. J. Boyton, O. V. Bracken, B. O'Brien, T. Brooks, N. Bullock, D. K. Butler, G. Captur, O. Carr,
413		N. Champion, C. Chan, A. Chandran, T. Coleman, J. Couto de Sousa, X. Couto-Parada, E. Cross, T.
414		Cutino-Moguel, S. D'Arcangelo, R. H. Davies, B. Douglas, C. Di Genova, K. Dieobi-Anene, M. O. Diniz,
415		A. Ellis, K. Feehan, M. Finlay, M. Fontana, N. Forooghi, S. Francis, J. M. Gibbons, D. Gillespie, D. Gilroy,
416		M. Hamblin, G. Harker, G. Hemingway, J. Hewson, W. Heywood, L. M. Hickling, B. Hicks, A. D.
417		Hingorani, L. Howes, I. Itua, V. Jardim, W. J. Lee, M. Jensen, J. Jones, M. Jones, G. Joy, V. Kapil, C.
418		Kelly, H. Kurdi, J. Lambourne, K. M. Lin, S. Liu, A. Lloyd, S. Louth, M. K. Maini, V. Mandadapu, C.
419		Manisty, Á. McKnight, K. Menacho, C. Mfuko, K. Mills, S. Millward, O. Mitchelmore, C. Moon, J. Moon,
420		D. Muñoz Sandoval, S. M. Murray, M. Noursadeghi, A. Otter, C. Pade, S. Palma, R. Parker, K. Patel, M.
421		Pawarova, S. E. Petersen, B. Piniera, F. P. Pieper, L. Rannigan, A. Rapala, C. J. Reynolds, A. Richards, M.
422		Robathan, J. Rosenheim, C. Rowe, M. Royds, J. Sackville West, G. Sambile, N. M. Schmidt, H. Selman,
423		A. Semper, A. Seraphim, M. Simion, A. Smit, M. Sugimoto, L. Swadling, S. Taylor, N. Temperton, S.
424		Thomas, G. D. Thornton, T. A. Treibel, A. Tucker, A. Varghese, J. Veerapen, M. Vijayakumar, T. Warner,
425		S. Welch, H. White, T. Wodehouse, L. Wynne, D. Zahedi, B. Chain, J. C. Moon, Immune boosting by
426		B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science (New York, N.Y.), eabq1841
427		(2022).
428	16.	Y. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, S. Du, J. Wang, Q. Li, X. Chen, Y. Yu, P. Wang,
429		Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W. Zhang, D. Zhao, J.
430		Zheng, L. Yu, C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai, Y. Hu, Y. Shi, L. Zheng, Z.
431		Li, Q. Gu, F. Shao, W. Huang, R. Jin, Z. Shen, Y. Wang, X. Wang, J. Xiao, X. S. Xie, BA.2.12.1, BA.4 and
432		BA.5 escape antibodies elicited by Omicron infection. Nature, (2022).
433	17.	E. Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company
434		reports. BMJ (Clinical research ed.) 375, n2713 (2021).
435	18.	T. Burki, The future of Paxlovid for COVID-19. The Lancet. Respiratory medicine, (2022).

- 436 19. D. Phizackerley, Three more points about Paxlovid for covid-19. *BMJ (Clinical research ed.)* **377**, o1397
- 437 (2022).
- D. The Lancet Infectious, Unmet need for COVID-19 therapies in community settings. *The Lancet*. *Infectious diseases* 21, 1471 (2021).
- E. Dolgin, The race for antiviral drugs to beat COVID and the next pandemic. *Nature* 592, 340-343
 (2021).
- 442 22. E. J. Rubin, L. R. Baden, S. Morrissey, Audio Interview: A Potential New Agent to Treat Covid-19. *The*443 *New England journal of medicine* 385, e101 (2021).
- 444 23. M. J. Levin, A. Ustianowski, S. De Wit, O. Launay, M. Avila, A. Templeton, Y. Yuan, S. Seegobin, A.
- 445 Ellery, D. J. Levinson, P. Ambery, R. H. Arends, R. Beavon, K. Dey, P. Garbes, E. J. Kelly, G. Koh, K. A.
- 446 Near, K. W. Padilla, K. Psachoulia, A. Sharbaugh, K. Streicher, M. N. Pangalos, M. T. Esser,
- Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. *The New England journal*of medicine **386**, 2188-2200 (2022).
- 449 24. Y. M. Loo, P. M. McTamney, R. H. Arends, M. E. Abram, A. A. Aksyuk, S. Diallo, D. J. Flores, E. J.
- 450 Kelly, K. Ren, R. Roque, K. Rosenthal, K. Streicher, K. M. Tuffy, N. J. Bond, O. Cornwell, J. Bouquet, L.
- 451 I. Cheng, J. Dunyak, Y. Huang, A. I. Rosenbaum, V. Pilla Reddy, H. Andersen, R. H. Carnahan, J. E.
- 452 Crowe, Jr., A. I. Kuehne, A. S. Herbert, J. M. Dye, H. Bright, N. L. Kallewaard, M. N. Pangalos, M. T.
- 453 Esser, The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates
- 454 and has an extended half-life in humans. *Science translational medicine* **14**, eab18124 (2022).
- 455 25. R. Stuver, G. L. Shah, N. S. Korde, L. E. Roeker, A. R. Mato, C. L. Batlevi, D. J. Chung, S. Doddi, L.
- 456 Falchi, B. Gyurkocza, A. Hamilton, Y. H. Lin, A. A. Jakubowski, E. Joffe, H. L. Landau, R. J. Lin, S.
- 457 Mailankody, M. L. Palomba, J. H. Park, M. A. Perales, D. M. Ponce, L. V. Ramanathan, G. A. Salles, M.
- 458 Scordo, S. K. Seo, U. A. Shah, E. M. Stein, D. Straus, S. Z. Usmani, J. W. Young, A. D. Zelenetz, A. Noy,
- 459 S. A. Vardhana, Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients
- 460 with hematologic malignancies. *Cancer cell* **40**, 590-591 (2022).
- 461 26. R. Rubin, Questions Remain About Who Will Get Monoclonal Antibodies for COVID-19 Preexposure
 462 Prophylaxis. *Jama* 327, 207-208 (2022).

- 463 27. R. Rubin, Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for
 464 Some People. *Jama* 326, 1895-1897 (2021).
- 465 28. A. C. Hunt, J. B. Case, Y. J. Park, L. Cao, K. Wu, A. C. Walls, Z. Liu, J. E. Bowen, H. W. Yeh, S. Saini, L.
- 466 Helms, Y. T. Zhao, T. Y. Hsiang, T. N. Starr, I. Goreshnik, L. Kozodoy, L. Carter, R. Ravichandran, L. B.
- 467 Green, W. L. Matochko, C. A. Thomson, B. Vögeli, A. Krüger, L. A. VanBlargan, R. E. Chen, B. Ying, A.
- 468 L. Bailey, N. M. Kafai, S. E. Boyken, A. Ljubetič, N. Edman, G. Ueda, C. M. Chow, M. Johnson, A.
- Addetia, M. J. Navarro, N. Panpradist, M. Gale, Jr., B. S. Freedman, J. D. Bloom, H. Ruohola-Baker, S. P.
- 470 J. Whelan, L. Stewart, M. S. Diamond, D. Veesler, M. C. Jewett, D. Baker, Multivalent designed proteins
- 471 neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. *Science*
- 472 *translational medicine* **14**, eabn1252 (2022).
- W. Fan, S. Sun, N. Zhang, Y. Zhang, P. Jiao, J. Wang, G. F. Gao, W. Liu, Y. Bi, L. Yang, Nasal delivery of
 thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection. *Signal transduction and targeted therapy* 7, 55 (2022).
- J. Ou, Y. Zhang, Y. Wang, Z. Zhang, H. Wei, J. Yu, Q. Wang, G. Wang, B. Zhang, C. Wang, ACE2Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. *Signal transduction and targeted therapy* 7, 43 (2022).
- 479 31. X. Zhang, H. Zhang, T. Li, S. Chen, F. Luo, J. Zhou, P. Zheng, S. Song, Y. Wu, T. Jin, N. Tang, A. Jin, C.
- 480 Yang, G. Cheng, R. Gong, S. Chiu, A. Huang, A potent neutralizing antibody provides protection against
- 481 SARS-CoV-2 Omicron and Delta variants via nasal delivery. *Signal transduction and targeted therapy* 7,
 482 301 (2022).
- 483 32. Z. Ku, X. Xie, P. R. Hinton, X. Liu, X. Ye, A. E. Muruato, D. C. Ng, S. Biswas, J. Zou, Y. Liu, D. Pandya,
- 484 V. D. Menachery, S. Rahman, Y. A. Cao, H. Deng, W. Xiong, K. B. Carlin, J. Liu, H. Su, E. J. Haanes, B.
- A. Keyt, N. Zhang, S. F. Carroll, P. Y. Shi, Z. An, Nasal delivery of an IgM offers broad protection from
 SARS-CoV-2 variants. *Nature* 595, 718-723 (2021).
- 487 33. X. Wu, L. Cheng, M. Fu, B. Huang, L. Zhu, S. Xu, H. Shi, D. Zhang, H. Yuan, W. Nawaz, P. Yang, Q. Hu,
- Y. Liu, Z. Wu, A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via
 intranasal administration. *Cell reports* 37, 109869 (2021).

490	34.	H. A. Parray, S. Shukla	. R. Perween	. R. Khatri	. T. Shrivastava.	V. Singh, P. Murugave	lu, S. Ahmed, S.
120	U	II. II. I alla j, D. Dilania		, IC. ISIICCII	,	, , , Diligin, I , Italagave	in, o. i minou, o

- 491 Samal, C. Sharma, S. Sinha, K. Luthra, R. Kumar, Inhalation monoclonal antibody therapy: a new way to
- treat and manage respiratory infections. *Applied microbiology and biotechnology* **105**, 6315-6332 (2021).
- 493 35. E. Bequignon, C. Dhommée, C. Angely, L. Thomas, M. Bottier, E. Escudier, D. Isabey, A. Coste, B. Louis,
- 494 J. F. Papon, V. Gouilleux-Gruart, FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal
- 495 Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? *International journal of* 496 *molecular sciences* 20, (2019).
- Y. Al Ojaimi, T. Blin, J. Lamamy, M. Gracia, A. Pitiot, C. Denevault-Sabourin, N. Joubert, J. P. Pouget, V.
 Gouilleux-Gruart, N. Heuzé-Vourc'h, D. Lanznaster, S. Poty, T. Sécher, Therapeutic antibodies natural
 and pathological barriers and strategies to overcome them. *Pharmacology & therapeutics* 233, 108022
- 500 (2022).
- J. T. Sockolosky, M. R. Tiffany, F. C. Szoka, Engineering neonatal Fc receptor-mediated recycling and
 transcytosis in recombinant proteins by short terminal peptide extensions. *Proceedings of the National Academy of Sciences of the United States of America* 109, 16095-16100 (2012).
- 504 38. X. Han, Y. Wang, S. Li, C. Hu, T. Li, C. Gu, K. Wang, M. Shen, J. Wang, J. Hu, R. Wu, S. Mu, F. Gong,
- 505 Q. Chen, F. Gao, J. Huang, Y. Long, F. Luo, S. Song, S. Long, Y. Hao, L. Li, Y. Wu, W. Xu, X. Cai, Q.
- 506 Gao, G. Zhang, C. He, K. Deng, L. Du, Y. Nai, W. Wang, Y. Xie, D. Qu, A. Huang, N. Tang, A. Jin, A
- 507 Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.
- 508 Frontiers in immunology **12**, 653189 (2021).
- 509 39. T. Li, X. Han, C. Gu, H. Guo, H. Zhang, Y. Wang, C. Hu, K. Wang, F. Liu, F. Luo, Y. Zhang, J. Hu, W.
- 510 Wang, S. Li, Y. Hao, M. Shen, J. Huang, Y. Long, S. Song, R. Wu, S. Mu, Q. Chen, F. Gao, J. Wang, S.
- 511 Long, L. Li, Y. Wu, Y. Gao, W. Xu, X. Cai, D. Qu, Z. Zhang, H. Zhang, N. Li, Q. Gao, G. Zhang, C. He,
- 512 W. Wang, X. Ji, N. Tang, Z. Yuan, Y. Xie, H. Yang, B. Zhang, A. Huang, A. Jin, Potent SARS-CoV-2
- 513 neutralizing antibodies with protective efficacy against newly emerged mutational variants. *Nature*
- 514 *communications* **12**, 6304 (2021).
- F. Gao, J. Huang, T. Li, C. Hu, M. Shen, S. Mu, F. Luo, S. Song, Y. Hao, W. Wang, X. Han, C. Qian, Y.
 Wang, R. Wu, L. Li, S. Li, A. Jin, A Highly Conserved Peptide Vaccine Candidate Activates Both

517	Humanal and Callular Immunity Assingt CARC CaV 2 Variant Staring Engutions in immunut and 12
517	Humoral and Centular Immunity Against SAKS-Cov-2 variant Strains. Frontiers in immunology 12.

518 789905 (2021).

- 519 41. R. Rockett, K. Basile, S. Maddocks, W. Fong, J. E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra,
- 520 M. Gall, J. Draper, E. Martinez, E. M. Sim, C. Lee, C. Ngo, M. Ramsperger, A. N. Ginn, Q. Wang, M.
- 521 Fennell, D. Ko, H. L. Lim, N. Gilroy, M. V. N. O'Sullivan, S. C. Chen, J. Kok, D. E. Dwyer, V.
- 522 Sintchenko, Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. *The New England*
- *journal of medicine* **386**, 1477-1479 (2022).
- 42. Z. Ku, X. Xie, E. Davidson, X. Ye, H. Su, V. D. Menachery, Y. Li, Z. Yuan, X. Zhang, A. E. Muruato, I. E.
- 525 AG, B. Tyrell, K. Doolan, B. J. Doranz, D. Wrapp, P. F. Bates, J. S. McLellan, S. R. Weiss, N. Zhang, P.
- 526 Y. Shi, Z. An, Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2
- 527 escape. *Nature communications* **12**, 469 (2021).
- 43. S. T. Sonnleitner, M. Prelog, S. Sonnleitner, E. Hinterbichler, H. Halbfurter, D. B. C. Kopecky, G.
- 529 Almanzar, S. Koblmüller, C. Sturmbauer, L. Feist, R. Horres, W. Posch, G. Walder, Cumulative SARS-
- CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral
 evolution within the host. *Nature communications* 13, 2560 (2022).
- 532 44. D. Li, G. D. Sempowski, K. O. Saunders, P. Acharya, B. F. Haynes, SARS-CoV-2 Neutralizing Antibodies
 533 for COVID-19 Prevention and Treatment. *Annual review of medicine* 73, 1-16 (2022).
- 45. T. Shapira, I. A. Monreal, S. P. Dion, D. W. Buchholz, B. Imbiakha, A. D. Olmstead, M. Jager, A. Désilets,
- 535 G. Gao, M. Martins, T. Vandal, C. A. H. Thompson, A. Chin, W. D. Rees, T. Steiner, I. R. Nabi, E.
- 536 Marsault, J. Sahler, D. G. Diel, G. R. Van de Walle, A. August, G. R. Whittaker, P. L. Boudreault, R.
- Leduc, H. C. Aguilar, F. Jean, A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and
 therapeutic. *Nature* 605, 340-348 (2022).
- 46. C. Zhu, J. Y. Lee, J. Z. Woo, L. Xu, X. Nguyenla, L. H. Yamashiro, F. Ji, S. B. Biering, E. Van Dis, F.
- 540 Gonzalez, D. Fox, E. Wehri, A. Rustagi, B. A. Pinsky, J. Schaletzky, C. A. Blish, C. Chiu, E. Harris, R. I.
- 541 Sadreyev, S. Stanley, S. Kauppinen, S. Rouskin, A. M. Näär, An intranasal ASO therapeutic targeting
- 542 SARS-CoV-2. *Nature communications* **13**, 4503 (2022).
- M. Ibrahim, R. Verma, L. Garcia-Contreras, Inhalation drug delivery devices: technology update. *Medical devices (Auckland, N.Z.)* 8, 131-139 (2015).

$\mathcal{A}_{\mathcal{A}}$. H. D	Huang.	. L.	C.	Li.	B .	Zhu.	Y.	Si.	R.	H.	ng, F	. Zhang	W.	"Zhang.	. I	. Hu	ang. B	. V	G.	. X.	Yang.	L.	. X.	Zhou.	Ρ.	48.	545
-----------------------------	--------	--------	------	----	-----	------------	------	----	-----	----	----	-------	---------	----	---------	-----	------	--------	-----	----	------	-------	----	------	-------	----	-----	-----

- 546 Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K.
- 547 Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A pneumonia
- 548 outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273 (2020).
- 549 49. H. Guo, Y. Gao, T. Li, T. Li, Y. Lu, L. Zheng, Y. Liu, T. Yang, F. Luo, S. Song, W. Wang, X. Yang, H. C.
- 550 Nguyen, H. Zhang, A. Huang, A. Jin, H. Yang, Z. Rao, X. Ji, Structures of Omicron spike complexes and
- 551 implications for neutralizing antibody development. *Cell reports* **39**, 110770 (2022).
- 552 50. I. Kimura, Y. Kosugi, J. Wu, J. Zahradnik, D. Yamasoba, E. P. Butlertanaka, Y. L. Tanaka, K. Uriu, Y.
- 553 Liu, N. Morizako, K. Shirakawa, Y. Kazuma, R. Nomura, Y. Horisawa, K. Tokunaga, T. Ueno, A. Takaori-
- Kondo, G. Schreiber, H. Arase, C. Motozono, A. Saito, S. Nakagawa, K. Sato, The SARS-CoV-2 Lambda
 variant exhibits enhanced infectivity and immune resistance. *Cell reports* 38, 110218 (2022).
- 556 51. S. Zhao, H. Zhang, X. Yang, H. Zhang, Y. Chen, Y. Zhan, X. Zhang, R. Jiang, M. Liu, L. Liu, L. Chen, W.
- Tang, C. Peng, X. Gao, Z. Zhang, Z. Shi, R. Gong, Identification of potent human neutralizing antibodies
 against SARS-CoV-2 implications for development of therapeutics and prophylactics. *Nature*
- *communications* **12**, 4887 (2021).
- 560 52. D. N. Mastronarde, Automated electron microscope tomography using robust prediction of specimen
 561 movements. *J Struct Biol* 152, 36-51 (2005).
- 562 53. S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: anisotropic
 563 correction of beam-induced motion for improved cryo-electron microscopy. *Nature Methods* 14, 331-332
 564 (2017).
- 565 54. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid unsupervised
 566 cryo-EM structure determination. *Nature Methods* 14, 290-296 (2017).
- 567 55. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin,
- 568 UCSF Chimera-A visualization system for exploratory research and analysis. *Journal of Computational* 569 *Chemistry* 25, 1605-1612 (2004).
- 56. L. A. Kelley, S. Mezulis, C. M. Yates, M. N. Wass, M. J. E. Sternberg, The Phyre2 web portal for protein
 modeling, prediction and analysis. *Nature Protocols* 10, 845-858 (2015).

- 572 57. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta
- 573 *Crystallographica Section D* **66**, 486-501 (2010).
- 574 58. D. Liebschner, P. V. Afonine, M. L. Baker, G. Bunkoczi, V. B. Chen, T. I. Croll, B. Hintze, L.-W. Hung, S.
- 575 Jain, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, B. K. Poon, M. G. Prisant, R. J. Read, J. S. Richardson,
- 576 D. C. Richardson, M. D. Sammito, O. V. Sobolev, D. H. Stockwell, T. C. Terwilliger, A. G. Urzhumtsev,
- 577 L. L. Videau, C. J. Williams, P. D. Adams, Macromolecular structure determination using X-rays, neutrons
- 578 and electrons: recent developments in Phenix. Acta Crystallographica Section D 75, 861-877 (2019).
- 579 59. L. Feng, Q. Wang, C. Shan, C. Yang, Y. Feng, J. Wu, X. Liu, Y. Zhou, R. Jiang, P. Hu, An adenovirus-
- 580 vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. *Nature*
- 581 *communications* **11**, 1-11 (2020).
- 582 60. Y. N. Zhang, X. D. Li, Z. R. Zhang, H. Q. Zhang, B. Zhang, A mouse model for SARS-CoV-2 infection by
- 583 exogenous delivery of hACE2 using alphavirus replicon particles. *Cell Research*, 1-3 (2020).

584	
585	
586	Acknowledgments:
587	We thank the Center for Animal Experiment and BSL-3 laboratory, Wuhan Institute of Virology,
588	Chinese Academy of Sciences; Center for Biosafety Mega-Science, Chinese Academy of
589	Sciences; and the National Virus Resource Center for resource support.
590	Funding:
591	The Natural Science Foundation of Hubei Province of China (2019CFA076)
592	The National Natural Science Foundation of China (32170949, 81871639, 92169109, 81871656
593	and 8181101099)
594	The National Science and Technology Major Project (2017ZX10202203)
595	The National Key Research and Development Program of China (2018YFA0507100 and
596	2016YFD0500300);
597	Guangzhou National Laboratory (SRPG22-015)
598	Lingang Laboratory (LG202101-01-07)
599	Science and Technology Commission of Shanghai Municipality (YDZX20213100001556 and
600	20XD1422900).
601	The first-in-human Investigator Initiated Study was funded by the Emergency Project from the

- 602 Science & Technology Commission of Chongqing (cstc2021jscx-fyzxX0001)
- 603 Author contributions:

604	A.H., S.C., A.J., H.Y., C.G. and C.Y. conceived and designed the project. For biological function
605	analysis of the NAbs, F.L., T.L., M.S., X.H., Y.W. and C.H. screened and cloned the antibodies,
606	and expressed and purified the antibodies; F.L., T.L. and W.W. were responsible for BLI assays
607	for the binding ability, affinity, and the competition experiment of NAbs; F.L., T.L., S.S., K.W.,
608	N.T., M.D., and S. L. prepared various pseudovirus and conducted the pseudovirus neutralization
609	assays. For the efficacy test of the NAbs in vitro and in vivo, X.Z., H.Z., J.Z., S.C., Y.W. and
610	R.G. performed authentic SARS-CoV-2 neutralization assays and animal experiments. For
611	structure analysis, H.G. and Y.L. cloned, expressed and purified Omicron BA.1 S proteins; H.G.,
612	Y.G., and Y.L. collected, processed the cryo-EM data, and built and refined the structure model;
613	X.J., H.Y. and T.J. analyzed and discussed the cryo-EM data. A.H., M.D., S.L., C.L., T.L., B.L.,
614	Y.T., C.Y., and G.C. designed and supported the investigator-initiated trial. A. H., S.C., A.J.,
615	X.J., R.G., X.Z. and F.L., Y.T., G.C. wrote the manuscript. All authors revised and reviewed the
616	final manuscript.
617	Competing interests:
618	Ailong Huang and Aishun Jin declare the following competing interests: Patent has been filed for

- some of the antibodies presented here (patent application number: PCT/CN2020/115480,
- 620 PCT/CN2021/078150, PCT/CN2021/113261; patent applicants: Chongqing Medical University).

621 All other authors declare no competing interests.

622 Data and materials availability:

- 623 The coordinates and cryo-EM map files for the 55A8-BA.1 S complexes and 55A8/58G6-BA.1
- 624 S complexes have been deposited in the Protein Data Bank (PDB) under accession number

625 7WWI, 7WWJ, 7WWK, 7XJ6, 7XJ8 and 7XJ9. All other data are available from the

626 corresponding author upon reasonable request.

627 Figures

628





630 The neutralizing potencies of 58G6, 55A8 and cocktail of 58G6 and 55A8 against SARS-CoV-2,

- 631 Omicron BA.1, BA.1.1, BA.2, BA.2.12.1 and BA.5 variants were measured with a pseudovirus
- neutralization assay. The dashed line indicates a 0% or 50% reduction in viral neutralization.
- 633 Data for each NAb were obtained from a representative neutralization experiment of two
- replicates, presented as mean values \pm SEM. (**B**) Neutralization against authentic SARS-CoV-2,
- 635 Delta and Omicron BA.1 viruses.



Fig. 2. Synergetic neutralizing mechanism of the cocktail of 58G6 and 55A8. (A)

- 638 Superposition of the locally refined Omicron RBD-ACE2 (PDB ID: 7WSA) model together with
- the locally refined Omicron RBD-55A8 Fab model. (**B**) Locally refined model of the 55A8 Fab
- and 58G6 Fab on the same up Omicron RBD. HC, heavy chain; LC, light chain. (C) 55A8 Fabs
- bind to Omicron S trimers in 2 states. Two perpendicular views of Omicron BA.1 S-55A8
- 642 complexes are shown as the surface. (D) 55A8 and 58G6 Fabs simultaneously bind to Omicron S
- trimers in 2 states. Two perpendicular views of Omicron S-55A8/58G6 complexes are shown as
- the surface. 55A8 heavy chain: salmon, 55A8 light chain: pink, 58G6 heavy chain: navy, 58G6
- light chain: sky blue, three Omicron RBDs: different shades of purple.



646

647 Fig. 3. Intranasal delivery of cocktail of 55A8 and 58G6 protect hamster from Omicron

- 648 **challenge.** Syrian golden hamsters challenged with 10^4 PFU of Omicron were treated with 58G6,
- 55A8 or the two-antibody cocktail at 1 h or 3 hrs pre-infection, or 3 hrs post-infection, and two
- additional treatments at 24 and 48 h post-infection. The turbinates, trachea and lungs were
- harvested on day 3 post-treatment and analyzed by viral RNA and infectious virus (by qRT–PCR
- and PFU/g). (A), (D) and (G) Animal experimental scheme. (B), (E) and (H) Viral RNA
- $(\log_{10}(\text{RNA copies per g}))$ was detected in the respiratory tract of hamsters (C), (F) and (I) The
- 654 infectious viruses (PFU) in the respiratory tract was measured with a viral plaque assay
- 655 performed with Vero E6 cells.

Cohort 1a (N=12)	Single day: 1 dose of 0.7 mg
Cohort 1b (N=12)	Single day: 2 dose of 0.7 mg; 4 hours per dose
Cohort 1c (N=12)	Single day: 2 dose of 0.7 mg; dose together
Cohort 1d (N=12)	Single day: 4 dose of 0.7 mg; 4 hours per dose
Cohort 2 (N=12)	Three days: 4 dose of 0.7 mg; 4 hours per dose
Cohort 3 (N=12)	Seven days: 4 dose of 0.7 mg; 4 hours per dose
Cohort 4 (N=36)	Fourteen days: 4 dose of 0.7 mg; 4 hours per dose

656

Fig. 4. Trial design for first-in-human study of 55A8/58G6 (A8G6) nasal spray

658 **neutralization antibody cocktail**. A total of 108 healthy volunteers were enrolled in 4 cohorts

of study. A8G6: Placebo = 5:1 for each cohort. Cohort 1 has 4 sub-cohorts, which focused on the

- study of different doses (1, 2, 4 doses) within one day of dosing. Cohort 2 to 4 focused on 4
- doses per day over 3, 7 and 14 days, respectively.



662

Fig. 5. Cohort 1 clinical study of 55A8/58G6 (A8G6) cocktail showed nasal NAbs concentration above the IC_{90} neutralization activity on Omicron BA.4/5.

665 concentration above the IC₉₀ neutralization activity on Omicron BA.4/5.

In each sub-cohort (1a, 1b, 1c, and 1d), 12 healthy volunteers were given different doses of cocktail NAbs (each dose is 560 μ g of 55A8 plus 140 μ g of 58G6, total 0.7 mg per dose) to both left and right nostril. A8G6 nasal spray: placebo nasal spray = 10:2. After A8G6 nasal spray, 5 volunteers took nasal samples at 0.25 hour post last dose at the left nostril, and at 1 hour post last dose at the right nostril; the other 5 took nasal samples at 4 hours post last dose at the left nostril

671 and at 8 hours at the right nostril; 24 hours and 72 hours after 1st dose, all 10 volunteers took the nasal swab at both left and right nostril. Nasal swab (containing ~50 µL of nasal surface mucus) 672 was washed in 500 µL PBS buffer before testing for A8G6 concentration using ELISA assay. 673 Nasal A8G6 concentration was predicted from A8G6 PBS wash concentration by multiple a 674 dilution factor of 11. Omicron BA.4/5 pseudovirus neutralization IC₉₀ and IC₉₉ values were 675 labeled as dashed line and dash/dot line, respectively. X-axis label legend of Cohort 1a: D-1 L is 676 the day before dosing; D1^{1st+15min} L is day 1 15 minutes after 1st dose left nostril nasal swab; 677 D1^{1st+1h}L is day 1 1 hour after 1st dose left nostril nasal swab; D1^{1st+4h}R is day 1 4 hours after 1st 678 dose right nostril nasal swab; D1^{1st+8h} R is day 1 8 hours after 1st dose right nostril nasal swab; 679 D2 L is 24 hours after day 1 1st dose left nostril swab; D2 R is 24 hours after day 1 1st dose right 680 nostril swab; D4 L is 72 hours after day 1 1st dose left nostril swab; D4 R is 72 hours after day 1 681 1st dose right nostril swab. X-axis label nomenclature of other Cohorts is similar to cohort1a. 682



683



```
685 concentration above the IC<sub>90</sub> neutralization activity on Omicron BA.4/5.
```

- In cohort 2-4, healthy volunteers were given 4 doses of cocktail NAbs (each dose is 560 µg of
- ⁶⁸⁷ 55A8 plus 140 μg of 58G6, total 0.7 mg per dose) per day over 3, 7 and 14 days, respectively.
- A8G6 nasal spray: placebo nasal spray = 10: 2. After A8G6 nasal spray, 5 volunteers took nasal

689	samples in alternate nostrils at each time point during dosing period, for a total of 4 time points
690	that account for total of 10 volunteers. During the follow up period, all 10 volunteers took the
691	nasal swab at both left and right nostril. Nasal swab (containing $\sim 50 \ \mu$ L of nasal surface mucus)
692	was washed in 500 μ L PBS buffer before testing for A8G6 concentration using ELISA assay.
693	Nasal A8G6 concentration was predicted from A8G6 PBS wash concentration by multiple a
694	dilution factor of 11. Omicron BA.4/5 pseudovirus neutralization IC_{90} and IC_{99} values were
695	labeled as dashed line and dash/dot line, respectively. X-axis label nomenclature is similar to
696	Fig. 5.



Fig.7. Selected nasal swab samples from cohort 1a and 1d showed > 90% neutralization

699 activity on Omicron BA.4/5.

- Selected nasal samples from cohort 1a and cohort 1d were checked for BA.4/5 neutralization
- activities using a pseudovirus neutralization assay. Nasal samples were first diluted 11-fold in
- 702 PBS then diluted 10-fold in cell culture media to measure their neutralization activities; the final
- neutralization activities in the original nasal samples were calculated by fitting a standard dose
- response curve.
- 705
- 706
- 707